Integra LifeSciences Holdings Corporation (IART) Balance Sheet

The $400B-plus equity decline between 2025Q1 and 2025Q2 coincides with a goodwill write-down from $1.1B to approximately $615M and a retained earnings collapse from $914.6M to $430.5M, indicating the balance sheet contraction is an accounting event rather than cash hemorrhage. Investors should view the post-Q2 2025 equity level of ~$1.0–$1.1B as the analytically relevant baseline, since the pre-impairment capital structure materially overstates the company's true loss-absorbing capacity. The stability of equity over the last four quarters at roughly $1.1B suggests the impairment cycle may have largely run its course, though the flat trajectory also signals no organic capital recovery underway.

Total debt has remained pinned at $2.0B across all ten quarters, implying locked-in, likely fixed-rate term debt with limited near-term refinancing pressure, though the maturity schedule is not visible in this data set. The D/E expansion from 1.31 to 1.88 therefore does not represent incremental risk-taking; rather, it signals that the company's debt load is now supported by a materially thinner equity cushion, reducing the margin of safety for creditors. With cash of only $252.3M against $2.0B of debt, net leverage sits at approximately 1.6x on trailing figures, which remains manageable for a medical device manufacturer generating positive operating cash flow but leaves limited room for error if remediation costs persist.

The impairment signals that the historical acquisition premium attached to prior deals—likely the Codman or ACell transactions—has been partially written off, suggesting those acquisitions did not deliver the anticipated returns. PPE has grown modestly from $521M to $577.3M over the same period, which is directionally positive but must be weighed against the cash flow analysis finding that capex has dropped to just 2.5% of revenue, well below depreciation of $37.1M per quarter. This combination—declining goodwill and underfunded PPE reinvestment—suggests the asset base is becoming more tangible on paper but may be physically deteriorating in real terms, a meaningful concern for a manufacturer dependent on specialized tissue-processing facilities.